What Are Warrants & How Do They Unlock Capital?

July 25, 2022

What exactly is a 'Warrant"?

Warrants are a derivative that give the right, but not the obligation, to buy or sell a security at a certain price before an expiration date. The most common type of security is equity or a common share.

Companies can leverage warrants when executing a capital raise, to offer multiple security types - a typical structure often includes what is referred to as a Common Share and a Warrant.

There are two types of warrants - a call warrant and a put warrant. Call warrants are the most common found in capital raise offerings. A call warrant is a security type which allows the purchaser to buy more securities in the future, at a predetermined exercise price. An investor can “exercise” their warrant by using it to purchase more securities before the “expiry period”, after which it cannot be exercised. Put warrants give the holder the right to sell an underlying asset for a specified price on or before a preset/expiration date.

Note: warrants do not pay dividends or come with voting rights. Investors are attracted to warrants as a means of leveraging their positions in a security, hedging against downside (for example, by combining a put warrant with a long position in the underlying stock), or exploiting arbitrage opportunities.

Key components of a Call Warrant:

  • Strike or exercise price: The price at which the investor can purchase shares of stock based on the terms of the warrant. This is also known as the pricing mechanism. 
  • Expiration date: This is the last day you can exercise a warrant.
  • Warrant price: This is the premium the issuer charges to purchase the warrant. It's usually set as a price-per-share and provides capital to the issuer upon sale.
  • Warrant shares: This is the number of shares the holder can purchase when exercising the warrant and the method of how they will be calculated.   

Advantages to including warrants in your raise:

Using warrants in pre-IPO capital raise offerings provides companies/issuers with the opportunity to unlock more capital at a future date with very little extra effort. Depending on the exercise period, warrants ultimately extend the time horizon for potentially raising equity - which allows the issuer to raise more capital. In pre-IPO offerings, warrants can be viewed to investors as a “sweetener” or an extra incentive for being one of the first to invest since they are speculating that when getting in early the future share price will appreciate and make their exercise favorable. Warrants are also a great mechanism for issuers to keep their investor base engaged and involved in the company. 

Exercising Warrants 

Traditionally, retail investors have been limited by a manual process to exercise their warrants, leading to many investors simply not exercising their warrants by the expiry date because ultimately it was a larger pain than the benefit it yielded. Due to this challenge, capital-raising companies have often opted not to include warrants in their equity crowdfunding campaign. DealMaker has transformed this manual process with our industry leading Warrant Portals which offers investors a seamless fully-digital experience to exercise the warrants they hold, leading to higher conversion and unlocked capital for issuers.

Our process automation sends out reminders to investors to exercise their warrants prior to the expiry date and ensures that expired warrants are unable to exercise. With a fully integrated solution, DealMaker acts as your warrant agent, transfer agent, and also provides a concierge service for smooth set-up and enhanced ongoing support.

DealMaker’s Warrant Portals saw issuers raise nearly $20M of additional capital in the past year

Investors do in fact like the option of warrants, with many viewing it as a sweetener on the deal. The major pitfall in warrants for investors has been the cumbersome avenues previously needed to execute on them. With the right tools in place to execute warrants efficiently, they can offer issuers access to untapped capital and can be a fundamental tool in growing their business. 

“The foregoing is market commentary only. Any market participant should do their own research and make informed decisions with their own advisors to make sure the particulars of their capital raise are correct for that particular issuer in that circumstance.”

Monogram Case Study - DealMaker (Embed)

When VCs said no, Monogram turned to retail investors. That decision powered their rise from startup to publicly traded company—and even helped them raise an additional $13M privately after their Nasdaq debut.

Monogram at NASDAQ celebration

The Challenge: Raising Capital on Their Terms

The Challenge: Raising on Their Terms

Monogram Technologies was founded with a bold vision: to revolutionize orthopedic surgery with a robotic joint replacement system using custom 3D-printed joints. The market for this technology is massive—approximately $19.6 billion, with over 1 million knee replacements per year. But it's a capital-intensive, regulation-heavy space—and traditional VCs weren't biting.

Instead of compromising, co-founders Dr. Doug Unis and Ben Sexson went all-in on a different path: retail capital. Why?

  • Control and ownership: Not only were they able to raise the capital they needed to grow the business—they did it on their own terms.
  • Long-term asset: They wanted to build an army of true believers who wanted to see the company succeed and would continue to reinvest over the years.
  • A value-add network: Raising from retail allowed Monogram to amass a waiting list of thousands of patients eager to participate in future trials.
  • Aligned incentives: Their mission to improve patient outcomes and build a better future for those struggling with joint pain resonated with retail investors.

The Power of Retail: Monogram's Capital Journey

Start Date End Date Type Platform Amount Raised # Investors
3/13/193/31/20A+SeedInvest$14,588,6686,000
11/16/201/16/21A+StartEngine$2,965,5018,000
1/17/212/18/22A+StartEngine$23,647,85314,082
7/15/223/16/23CFDealMaker$4,673,0002,249
3/1/234/8/23A+Republic$232,275120
3/1/235/23/23A+DealMaker$15,958,3645,198
5/18/23-Nasdaq listing
7/2410/24Unit OfferingDealMaker$12,990,1032,745

Monogram Capital Raise Timeline

Monogram's first direct-to-investor raise was a $14.6M round in 2019. Since then, Monogram has raised retail capital six additional times, using Reg A+ as a springboard to a Nasdaq listing in 2023.

Each raise brought in new believers—and more importantly, kept bringing them back. That's the long-term power of retail capital. It's not just one campaign—it's a compounding asset that grows with the business.

$80M+
Raised across seven campaigns
~40,000
Investors championing Monogram's vision
20%
Of each raise came from previous investors

Marketing Excellence

DealMaker Reach provided strategic investor acquisition services, helping Monogram connect with the right audience through high-impact channels.

Premium Publications

Targeted campaigns in premium publications like Morning Brew captured qualified investors

High-Engagement Webinars

Engaging events that generated over $4.3 million in investments

Community Building

Strategic approaches that fostered a loyal shareholder base

Investment Momentum

Innovative approaches that amplified investment momentum

Monogram's Journey to Success

Monogram's journey has been defined by relentless innovation, strategic fundraising, and breakthrough advancements in robotic-assisted joint replacement. From early-stage research to a Nasdaq listing and beyond, Monogram's milestones reflect its evolution into a pioneering force in orthopedic surgery:

  • Filed its first patent application in 2017
  • Conducted clinical studies at UCLA and University of Nebraska
  • Expanded the team with key hires
  • Attracted a top-tier advisory board to guide clinical innovations
  • Signed their first distribution partnerships
  • Made headlines with cutting-edge live demonstrations
  • Secured 501(k) FDA clearance for the mBôs surgical system

Nasdaq Debut & Beyond

In May 2023, Monogram Orthopaedics successfully listed on the Nasdaq—a significant milestone offering liquidity and growth opportunities for the company.

For most companies, that would be the end of their story in the private markets. But for Monogram, it was just the beginning of a new chapter.

Public perception says you can't raise privately post-IPO. Monogram proved that wrong.

Defying conventional fundraising norms, Monogram raised an additional $13 million from private investors, powered by DealMaker. This move highlighted the power of a dedicated investor community and provided additional strategic growth capital. Meanwhile, strategic digital marketing for the private offering helped boost the public share price—a win-win for the company and its investors, both public and private.

This was retail capital at its best: strategic, repeatable, and aligned.

One vision. Zero compromises.

This wasn't a one-time raise. It was a multi-year capital strategy.

Retail capital helped Monogram:

  • Go from concept to commercialization without relying on VCs
  • Retain ownership and control in a high-burn industry
  • Build a base of loyal shareholders who invested not once, but over and over again
  • Uplist to the Nasdaq, and still keep raising post-IPO

This is what makes retail capital different. It doesn't expire—it compounds. And DealMaker is built to maximize that long-term value.

Dr. Doug Unis Quote
Ben Sexson Quote

Ready to Raise Capital on Your Terms?

Whether you're pre-revenue or post-IPO, DealMaker gives you the infrastructure, support, and strategy to raise from the people who believe in you most.

Explore Raising Capital with DealMaker
DealMaker Logo

The ultimate technology for raising capital online

Talk to the experts
The ultimate technology for raising capital online - talk to the experts